

Predictors of Clinical Outcomes among People with HIV and Tuberculosis Symptoms after Rapid Treatment Initiation in Haiti

¹Aaron RICHTERMAN*, ²Nancy DORVIL*, ²Vanessa RIVERA, ³Heejung BANG, ²Patrice SEVERE, ²Kerylyne LAVOILE, ²Samuel PIERRE, ²Alexandra APOLLON, ²Emelyne DUMOND, ²Guylaine PIERRE LOUIS FORESTAL, ^{2,5}Vanessa ROUZIER, ²Patrice JOSEPH, ⁴Pierre-Yves CREMIEUX, ^{2,5}Jean W PAPE, ⁶Serena P KOENIG

*co-first authors

Keywords: HIV; Rapid Antiretroviral Therapy Initiation; Outcome Predictors; Haiti

Abbreviations: AIDS, acquired Immunodeficiency syndrome; AOR, adjusted odds ratio; ART, antiretroviral therapy; BMI, body mass index; GHESKIO, Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections; HIV, human immunodeficiency virus; IQR, interquartile range; IPW, inverse probability weighting; NIH, National Institutes of Health; OR, odds ratio; WHO, World Health Organization; USD, United States Dollar

Corresponding author: Aaron Richterman; Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA (19104); e-mail:

aaron.richterman@penmedicine.upenn.edu

Alternative corresponding author: Serena Koenig; Brigham and Women's Hospital, 75 Francis Street, Boston, MA, United States of America; skoenig@bwh.harvard.edu

¹ University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America

² Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti

³ University of California, Davis School of Medicine, Davis, California, United States of America

⁴ Analysis Group, Boston, Massachusetts, United States of America

⁵ Weill Cornell Medical College, New York, New York, United States of America

⁶ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

1 **ABSTRACT**

2 *Introduction*

3 Few studies have evaluated baseline predictors of clinical outcomes among people with
4 HIV starting antiretroviral therapy (ART) in the modern era of rapid ART initiation.

5 *Methods*

6 We conducted a secondary analysis of a randomized controlled trial of two rapid
7 treatment initiation strategies for people with treatment-naïve HIV and tuberculosis
8 symptoms at an urban clinic in Haiti. We used logistic regression models to assess
9 associations between baseline characteristics and (1) retention in care at 48 weeks, (2)
10 HIV viral load suppression at 48 weeks (among participants who underwent viral load
11 testing), and (3) all-cause mortality.

12 *Results*

13 500 participants were enrolled in the study 11/2017-1/2020. Eighty-eight (18%)
14 participants were diagnosed with tuberculosis, and ART was started in 494 (99%). After
15 adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI
16 0.10-0.46), dolutegravir initiation (AOR 2.57, 95% CI 1.22-5.43), age (AOR 1.42 per 10-
17 year increase, 95% CI 1.01-1.99), and tuberculosis diagnosis (AOR 3.92, 95% CI 1.36-
18 11.28) were significantly associated with retention. Age (AOR 1.36, 95% CI 1.05-1.75),
19 dolutegravir initiation (AOR 1.75, 95% CI 1.07-2.85), and tuberculosis diagnosis (AOR
20 0.50, 95% CI 0.28-0.89) were associated with viral suppression. Higher CD4 cell count
21 at enrollment (unadjusted odds ratio [OR] 0.69, 95% CI 0.55-0.87) and anemia (OR
22 4.86, 95% CI 1.71-13.81) were associated with mortality.

23 *Conclusions*

24 We identified sociodemographic, treatment-related, clinical, and laboratory-based
25 predictors of clinical outcomes. These characteristics may serve as markers of sub-
26 populations that could benefit from additional interventions to support treatment success
27 after rapid treatment initiation.

28 INTRODUCTION

29 Rapid initiation of antiretroviral therapy (ART) after HIV diagnosis (i.e., within 7 days of
30 diagnosis, including same-day start) has been recommended by the World Health
31 Organization (WHO) since 2017.¹ The 2021 WHO guidelines recommend rapid initiation
32 for all people with HIV except for those with concern for meningitis (i.e., secondary to
33 cryptococcus or tuberculosis).² This recommendation was based on multiple
34 randomized controlled trials conducted in diverse settings and published over the last
35 decade.³⁻⁹ These trials demonstrated that rapid ART initiation results in improvements in
36 retention in care, viral load suppression, and mortality. There have been two
37 hypothesized mechanisms behind this benefit — first, that logistical burdens are
38 minimized; and second, that the more immediate provision of medicine facilitates a
39 sense of hope, optimism, and connection with the health system. While several
40 observational studies using real-world data have suggested that rapid ART initiation
41 may be associated with increased risk of loss to follow-up, these findings can largely be
42 attributed to biases inherent to the study design.¹⁰

43 People with newly diagnosed HIV commonly present with signs or symptoms
44 suggesting tuberculosis.¹¹ While the 2021 WHO guidelines acknowledged that there is
45 little information available about the risks or benefits of rapid ART initiation among
46 people with HIV and tuberculosis symptoms, they recommended rapid ART initiation
47 while investigating tuberculosis, with close follow-up within seven days to initiate
48 tuberculosis treatment if necessary. Since the publication of these guidelines, our group
49 has demonstrated high rates of ART initiation and retention in care among people with

50 HIV and tuberculosis symptoms in Haiti who were randomized to either of two rapid
51 treatment initiation strategies.¹²

52 While the recently shifting approach in ART initiation timing reflects the clearly apparent
53 benefits associated with a rapid start, this strategy necessitates a shorter window of
54 time to allow for the assessment of clinical or social risk factors for poor outcomes after
55 initiating ART. As a result, a key research priority in the rapid ART initiation era is to
56 identify readily available baseline characteristics associated with subsequent treatment
57 outcomes such as retention in care, viral suppression, and mortality. A better
58 understanding of these predictors may allow for the development of targeted
59 interventions for sub-populations of people starting ART who are vulnerable to poor
60 outcomes after rapid treatment initiation. To address this gap in the literature, we
61 evaluated baseline predictors of clinical outcomes in a randomized trial of two rapid
62 treatment initiation strategies for people with HIV and tuberculosis symptoms receiving
63 care in urban Haiti.¹²

64 **METHODS**

65 *Study Design and Oversight*

66 We conducted a secondary analysis of a previously reported open-label randomized
67 controlled trial of treatment initiation strategies for people with treatment-naïve HIV and
68 tuberculosis symptoms in Haiti (NCT03154320).¹² Our objective in this secondary
69 analysis was to evaluate baseline predictors of (1) retention in care, (2) HIV viral load
70 suppression at 48 weeks, and (3) all-cause mortality. Participants in the trial were
71 randomized 1:1 to either same-day treatment (same-day tuberculosis testing with same-

72 day tuberculosis treatment if diagnosed with tuberculosis; same-day ART if tuberculosis
73 not diagnosed) versus standard care (initiating tuberculosis treatment within seven days
74 and delaying ART to day seven if tuberculosis not diagnosed). For all participants
75 diagnosed with tuberculosis, ART was initiated two weeks after tuberculosis treatment.
76 The trial found no differences by study arm in the primary outcome of retention in care
77 with 48-week HIV-1 RNA <200 copies/mL. Additional details about the treatment
78 strategies and outcomes have previously been reported.¹² The trial was approved by
79 the institutional review boards at the Haitian Group for the Study of Kaposi's Sarcoma
80 and Opportunistic Infections (GHESKIO), Mass General Brigham, Florida International
81 University, and Weill Cornell Medical College.

82 *Setting*

83 The study was conducted at GHESKIO in Port-au-Prince, the urban, densely populated
84 capital of Haiti. During the study there was pervasive and ongoing geopolitical
85 instability, gang violence, and civil unrest in Haiti, with consequent economic instability
86 and hardship. GHESKIO is a Haitian nongovernmental organization and the largest
87 provider of HIV and tuberculosis care in the Caribbean. GHESKIO provides care for
88 approximately 15,000 people with HIV and >2,000 people with tuberculosis annually.
89 The adult HIV prevalence in Haiti is 1.7%, and the annual tuberculosis incidence is 154
90 per 100,000 persons.^{13,14} First-line treatment for HIV included co-formulated efavirenz,
91 tenofovir disoproxil fumarate, and lamivudine until December 2018, after which
92 dolutegravir became available and was preferred over efavirenz. During 2019, all
93 people with HIV receiving efavirenz-based regimens at GHESKIO were switched to a
94 dolutegravir-based regimen, regardless of viral load. Tuberculosis was treated

95 according to standard guidelines, and all participants who were not diagnosed with
96 tuberculosis disease were treated with prophylactic isoniazid.¹⁵ Based on recent clinical
97 trial results, participants with CD4 count <100 cells/mm³ received azithromycin for five
98 days, and those with CD4 count <100 cells/mm³ and tuberculosis received prednisone
99 prophylaxis.^{16,17} Retention activities at GHESKIO included: reminder phone calls (or
100 home visits for those without phones) prior to visits, and after missed visits; a
101 transportation subsidy of ~\$1 USD at each visit; and a ~\$1 USD phone card at each
102 visit.

103 *Study Population*

104 We included all participants enrolled in the original trial in this secondary analysis.¹²
105 Patients were eligible for inclusion in the trial if they had documented HIV-1 infection,
106 were ≥18 years of age, ART-naïve, and reported cough, fever, and/or night sweats of
107 any duration, and/or weight loss. Exclusion criteria included tuberculosis treatment in
108 the past year, lack of preparedness on an ART readiness questionnaire, pregnancy or
109 breastfeeding, active drug or alcohol use, a mental condition that would interfere with
110 completing study requirements, plans to transfer during the study period, symptoms
111 consistent with WHO stage 4 neurologic disease, or WHO “danger signs” of
112 temperature >39 degrees Celsius, pulse >120 beats/minute, respiratory rate >30
113 breaths/minute, or inability to walk unaided. All participants provided written informed
114 consent.

115 *Data*

116 Study procedures have been reported in detail elsewhere.¹² For the purposes of this
117 analysis, we included baseline demographic, clinical and laboratory data, as well as
118 outcome data 48 weeks after enrollment, all of which were extracted from the GHESKIO
119 electronic health record. Baselines variables included in this analysis were: age, sex,
120 income less than \$1 USD per day (self-report), educational attainment, marital status,
121 body mass index (BMI), CD4 cell count, tuberculosis diagnosis (microbiologically or
122 clinically diagnosed), and study arm (same-day or standard). We also included
123 information about the ART regimen that was initiated. Outcome variables included clinic
124 attendance at 48 weeks, HIV-1 RNA at 48 weeks, and mortality during 48 weeks of
125 follow-up.

126 *Outcomes*

127 We considered three outcomes in this analysis. Retention in care was defined as
128 attending a clinical visit 48 weeks after enrollment (with a prespecified window of +/-
129 twelve weeks). Viral load suppression was defined as having HIV-1 RNA < 200
130 copies/mL 48 weeks after enrollment (with a prespecified window of +/- twelve weeks),
131 and was evaluated among all participants who had undergone viral load testing within
132 that window. All-cause mortality over 48 weeks of follow-up after enrollment was
133 determined using family report (death certificates are not available in Haiti).

134 *Statistical Analysis*

135 Baseline characteristics were summarized using medians and interquartile ranges (IQR)
136 for continuous variables and frequencies and percentages for categorical/binary
137 variables.

138 We assessed predictors of retention in care, viral suppression, and mortality using
139 logistic regression models. We evaluated associations between our outcome variables
140 and the following baseline predictors: age (continuous variable, per 10 year increase),
141 female sex, income less than \$1 USD per day, less than secondary education, married,
142 undernutrition (BMI<18.5 kg/m²), CD4 cell count (continuous variable, per 50 cell/mm³
143 increase), anemia (NIH Division of AIDS Grade ≥3),¹⁸ tuberculosis diagnosis, and
144 randomization to the standard strategy study arm. Because first-line ART changed from
145 an efavirenz-based regimen to a dolutegravir-based regimen partway through the study,
146 we also included a binary variable indicating whether a participant had been initiated on
147 dolutegravir. We prespecified this set of 11 predictors and cutoffs for binary predictors
148 from clinical perspectives; we did not conduct model-based variable selection. We did
149 not adjust time-varying covariates that may be less relevant for prediction, or variables
150 that can be affected by study treatment/exposure (e.g., symptoms during follow-up).

151 We first evaluated univariable associations between predictors and the three outcomes.
152 We then generated multivariable models for the retention in care and viral load
153 suppression outcomes that included all predictors. We did not build a multivariable
154 model for the mortality outcome because there were few deaths (n=15).

155 Next, for the viral load suppression outcome, we additionally fitted an inverse probability
156 of (censoring) weighting regression model to account for potential selection bias
157 resulting from exclusion of 66 participants who did not undergo viral load testing at week
158 48.^{19,20} To do this, we weighted observations by the inverse probability that a given
159 participant had a viral load test performed. These probabilities of having non-missing (or

160 complete) data were fitted via multivariable logistic regression that included the 11
161 baseline covariates in this analysis.²⁰

162 We performed statistical analyses using SAS version 9.4 (SAS Institute, Cary, NC,
163 USA).

164 **RESULTS**

165 Out of 576 people screened for trial participation between November 2017 and January
166 2020, 500 were enrolled and are included in this analysis (Table 1).¹² Median age was
167 37 years (IQR 30 to 45), and 234 (47%) were female. Cough, fever, night sweats, and
168 weight loss were reported by 200 (47%), 194 (39%), 72 (14%), and 491 (98%)
169 participants, respectively. Median BMI was 20.6 (IQR: 18.7 to 22.9), and 116 (23%) met
170 criteria for undernutrition. Median hemoglobin was 11.8 g/dL (IQR: 10.1, 11.8), and 81
171 (16%) participants with available hemoglobin results (N=480) had Grade ≥ 3 anemia.¹⁸
172 Median CD4 count was 274 cells/mm³ (IQR 128 to 426), with 101 (20%) having CD4
173 count < 100 cells/mm³. Eighty-eight (18%) participants were diagnosed with tuberculosis
174 at baseline; of these, 68 (77%) were diagnosed microbiologically. All participants with
175 tuberculosis were started on first-line treatment for drug-susceptible tuberculosis.

176 Antiretroviral therapy was started in 494 (99%) participants — 407 (83%) who were not
177 diagnosed with tuberculosis at baseline, 69 (14%) who initiated ART after initiating
178 tuberculosis treatment, and 18 (4%) who initiated ART before initiating tuberculosis
179 treatment (e.g., in the context of positive culture after initial negative nucleic acid
180 amplification testing). Among participants who started ART, 310 (62%) initiated an
181 efavirenz-based regimen, and 184 (37%) initiated a dolutegravir-based regimen. Among

182 the 412 participants not diagnosed with tuberculosis at baseline, antiretroviral therapy
183 was initiated in 407 (98.8%) at a median time of 6 (IQR 0 to 7) days — 202 (49%) on
184 the day of HIV diagnosis, 110 (27%) within 7 days, 83 (20%) from 8 to 14 days, and 12
185 (3%) >14 days after HIV diagnosis. Among participants started on efavirenz, 158 (51%)
186 were transitioned to dolutegravir during the study period, a median of 245 days (IQR
187 201 to 289) after starting ART. Nine participants (2%) who were started on an efavirenz-
188 based regimen were switched to a second-line protease inhibitor-based regimen during
189 the study period.

190 There were 447 (89%) participants retained in care at week 48, among whom 431
191 (96%) underwent viral load testing. Among participants who underwent viral load
192 testing, 320 (72%) had HIV-1 RNA <200 copies/mL. Fifteen (3%) participants died
193 during the study period, with causes of death previously reported.¹²

194 In univariate analyses, less than secondary education (odds ratio [OR] 0.34, 95% CI
195 0.17 to 0.66) and initiating dolutegravir-based ART (OR 2.74, 95% CI 1.34 to 5.60) were
196 significantly associated with retention in care at 48 weeks (Table 2). After multivariable
197 adjustment, less than secondary education (adjusted odds ratio [AOR] 0.21, 95% CI
198 0.10 to 0.46) remained significantly associated with a reduced odds of retention in care.
199 Dolutegravir initiation (AOR 2.57, 95% CI 1.22 to 5.43), age (AOR 1.42 per 10 year
200 increase, 95% CI 1.01 to 1.99), and tuberculosis diagnosis at enrollment (AOR 3.92,
201 95% CI 1.36 to 11.28) were all significantly associated with increased odds of retention.
202 Among participants who underwent viral load testing at 48 weeks, age (OR 1.35 per 10
203 year increase, 95% CI 1.08 to 1.71), tuberculosis diagnosis (OR 0.42, 95% CI 0.25 to

204 0.69), and dolutegravir initiation (OR 1.81, 95% CI 1.13 to 2.90) were significantly
205 associated with viral suppression (Table 3). After multivariable adjustment, age (AOR
206 1.36, 95% CI 1.05 to 1.75) and dolutegravir initiation (AOR 1.75, 95% CI 1.07 to 2.85)
207 remained positively associated with viral suppression, and tuberculosis diagnosis (AOR
208 0.50, 95% CI 0.28 to 0.89) remained negatively associated with viral suppression.
209 Findings were similar after incorporating inverse probability weights to account for
210 participants who did not undergo viral load testing (Table 3). Weights ranged from 1.02
211 to 1.48, which means 1 complete case/person represented approximately 1 to 1.5
212 persons/observations from the overall population.

213 Higher CD4 cell count at enrollment was significantly associated with a lower odds of
214 mortality in unadjusted models (OR 0.69, 95% CI 0.55 to 0.87) (Table 4). Grade ≥ 3
215 anemia was associated with a significantly greater odds of mortality (OR 4.86, 95% CI
216 1.71 to 13.81).

217 **DISCUSSION**

218 In this study of 500 people with newly diagnosed HIV and tuberculosis symptoms (about
219 one in five of whom were diagnosed with tuberculosis) who participated in a randomized
220 trial of two rapid treatment initiation protocols, we identified sociodemographic (age,
221 educational attainment), treatment-related (dolutegravir-based regimens), clinical
222 (tuberculosis diagnosis), and laboratory-based (CD4 count and anemia) predictors of
223 clinical outcomes over a follow-up period of 48 weeks. Despite substantial geopolitical
224 instability in Haiti during the study period, nearly all participants initiated ART (over three
225 quarters of participants without tuberculosis started within 7 days) and retention in care

226 was high. This is one of the first studies to report baseline predictors of clinical
227 outcomes in the context of rapid ART initiation, especially among people experiencing
228 tuberculosis symptoms. The predictors we identified can be easily and quickly
229 measured during the condensed evaluation prior to rapid ART initiation, and may serve
230 as markers of sub-populations that could benefit from additional interventions to support
231 treatment success.

232 The two sociodemographic factors associated with poorer outcomes were younger age
233 (associated with lower retention in care and lower viral suppression rates) and less than
234 a secondary education (associated with lower retention in care). Both of these factors
235 have previously been identified as predictors of clinical outcomes in pre-rapid ART
236 initiation settings,²¹ and our findings demonstrate that they continue to be important
237 markers in the current era.

238 Education was the baseline characteristic most strongly associated with retention in
239 care. Education was also identified as a key driver of persistent disparities in life
240 expectancy among patients initiating ART at GHESKIO during earlier time periods.²²

241 Our results may reflect several potential mechanisms. First, lower education may have
242 been associated with lower health literacy, with greater consequent difficulty
243 communicating the benefits of ART and clinical follow-up. If this is the case, patients
244 with lower education levels may benefit from tools designed to facilitate effective and
245 rapid communication of key HIV-related concepts.^{23,24} While this may be exacerbated
246 by the shorter duration of pre-treatment counseling inherent to rapid ART initiation, as
247 we noted above this association was also described prior to the adoption of rapid ART
248 initiation.²¹ Second, this association may result from an unmeasured social or economic

249 factor that is correlated with education. For example, food insecurity tends to be strongly
250 associated with educational attainment, is highly prevalent in Haiti, and has been
251 associated with a wide variety of adverse HIV outcomes.²⁵⁻²⁸ More generally,
252 socioeconomic factors like poverty are associated with education and can strongly
253 influence HIV outcomes.²⁹ While future research should aim to disentangle these
254 potential mechanisms, educational level can be used in HIV programs as a prognostic
255 marker for clinical outcomes after treatment initiation.

256 Initiation of a dolutegravir-based regimen (versus an efavirenz-based regimen) was
257 associated with an increased odds of both retention in care and viral suppression. This
258 finding further supports the preference for dolutegravir as first-line therapy,² is
259 consistent with dolutegravir's greater tolerability and effectiveness relative to
260 efavirenz,³⁰ and illustrates the instrumental role that dolutegravir can play in improving
261 HIV-related population health. This is especially the case in settings with high rates of
262 efavirenz resistance among ART-naïve people with HIV, like Haiti.³¹ Of note, about half
263 the participants started on a efavirenz-based ART were transitioned to dolutegravir at
264 some point during the study period. This likely biased the association between
265 dolutegravir initiation and clinical outcomes towards the null, meaning that the benefits
266 of dolutegravir are likely to be even greater than those estimated in this study.

267 While all participants in this study were experiencing tuberculosis symptoms at
268 enrollment, only 18% were ultimately diagnosed with tuberculosis, and being diagnosed
269 with tuberculosis was significantly associated with greater odds of retention in care and
270 lower odds of viral suppression. Greater retention likely results from closer clinical
271 contact during tuberculosis treatment (e.g., directly observed therapy) and the fact that

272 people with tuberculosis commonly experience rapid improvement in symptoms on
273 therapy. Other studies have also reported an association between virologic failure and
274 tuberculosis co-infection.³²⁻³⁵ Lower odds of viral suppression after tuberculosis
275 diagnosis may relate to delays in ART initiation (although these tended to be short),
276 difficulty with drug tolerability given additional medications being administered.
277 Tuberculosis may also increase HIV viral load and the size of the HIV reservoir.

278 There were few deaths among participants during follow-up, and two baseline
279 laboratory characteristics were significantly associated with death — CD4 cell count and
280 anemia. Immunologic dysfunction from progressive HIV has long been recognized as a
281 key risk factor for death among people with HIV. Anemia, which may result from both
282 nutritional and non-nutritional (e.g., disseminated infection) mechanisms, has also been
283 identified as an important risk factor for mortality.^{36,37}

284 This study had several limitations. It was conducted among participants reporting
285 tuberculosis symptoms at a single large urban clinic with a high quality of care, which
286 may limit generalizability to other settings and contexts. Our viral suppression outcome
287 was assessed among participants who completed viral load testing at week 48, which
288 raises the possibility of selection bias. However, over 85% of participants underwent
289 viral load testing, and estimates from our missing data-adjusted analyses were nearly
290 identical to those from an unweighted multivariable model. Lastly, the odds ratios
291 reported here are associational, not casual, with non-randomized exposures, which is
292 typical in studies of identification of predictors or risk or protective factors.

293 **CONCLUSIONS**

294 In this study of 500 people with newly diagnosed HIV and tuberculosis symptoms (18%
295 of whom were diagnosed with tuberculosis) who participated in a trial of two rapid
296 treatment initiation protocols, we identified sociodemographic (age, educational
297 attainment), treatment-related (dolutegravir-based regimens), clinical (tuberculosis
298 diagnosis), and laboratory-based (CD4 count and anemia) predictors of clinical
299 outcomes over a follow-up period of 48 weeks. This is one of the first studies to report
300 baseline predictors of clinical outcomes in the context of rapid ART initiation, especially
301 among people reporting tuberculosis symptoms. The predictors we identified can be
302 easily and quickly assessed during the condensed evaluation prior to rapid ART
303 initiation, and may serve as markers of sub-populations that could benefit from
304 additional interventions to support treatment success.

305 **DECLARATIONS**

306 All authors declare no conflicts of interest.

307 **FUNDING**

308 This study was funded by a grant from the National Institute of Allergy and Infectious
309 Diseases (R01AI131998; primary investigator: SK). The funders had no role in study
310 design, data collection and analysis, decision to publish, or preparation of the
311 manuscript.

312 REFERENCES

- 313 1. World Health Organization Guidelines Review Committee. *Guidelines for managing advanced*
314 *HIV disease and rapid initiation of antiretroviral therapy*. Geneva, Switzerland: World Health
315 Organization;2017.
- 316 2. World Health Organization. *Consolidated guidelines on HIV prevention, testing, treatment,*
317 *service delivery and monitoring: recommendations for a public health approach*. Geneva,
318 Switzerland: World Health Organization;2021.
- 319 3. Labhardt ND, Ringera I, Lejone TI, et al. Effect of Offering Same-Day ART vs Usual Health Facility
320 Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults
321 With HIV in Lesotho: The CASCADE Randomized Clinical Trial. *Jama*. 2018;319(11):1103-1112.
- 322 4. Rosen S, Maskew M, Larson BA, et al. Simplified clinical algorithm for identifying patients eligible
323 for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in
324 South Africa and Kenya. *PLOS Medicine*. 2019;16(9):e1002912.
- 325 5. Amanyire G, Semitala FC, Namusobya J, et al. Effects of a multicomponent intervention to
326 streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised
327 trial. *The Lancet HIV*. 2016;3(11):e539-e548.
- 328 6. Stevens WS, Gous NM, MacLeod WB, et al. Multidisciplinary Point-of-Care Testing in South
329 African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention
330 in Care. *Journal of acquired immune deficiency syndromes (1999)*. 2017;76(1):65-73.
- 331 7. Koenig SP, Dorvil N, Dévieux JG, et al. Same-day HIV testing with initiation of antiretroviral
332 therapy versus standard care for persons living with HIV: A randomized unblinded trial. *PLoS*
333 *Med*. 2017;14(7):e1002357.
- 334 8. Rosen S, Maskew M, Fox MP, et al. Initiating Antiretroviral Therapy for HIV at a Patient's First
335 Clinic Visit: The RapIT Randomized Controlled Trial. *PLoS Med*. 2016;13(5):e1002015.
- 336 9. Maskew M, Brennan AT, Fox MP, et al. A clinical algorithm for same-day HIV treatment initiation
337 in settings with high TB symptom prevalence in South Africa: The SLATE II individually
338 randomized clinical trial. *PLOS Medicine*. 2020;17(8):e1003226.
- 339 10. Labhardt ND, Brown JA, Sass N, Ford N, Rosen S. Treatment Outcomes After Offering Same-Day
340 Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies
341 Between Different Studies. *Clinical Infectious Diseases*. 2023;77(8):1176-1184.
- 342 11. Burke RM, Rickman HM, Singh V, et al. Same-day antiretroviral therapy initiation for people
343 living with HIV who have tuberculosis symptoms: a systematic review. *HIV medicine*.
344 2022;23(1):4-15.
- 345 12. Dorvil N, Rivera VR, Riviere C, et al. Same-day testing with initiation of antiretroviral therapy or
346 tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms
347 at HIV diagnosis: A randomized open-label trial from Haiti. *PLoS Med*. 2023;20(6):e1004246.
- 348 13. Global Tuberculosis Program, World Health Organization, Country Profile. Haiti.
349 [https://worldhealthorg.shinyapps.io/tb_profiles/?inputs_entity_type=%22country%22&iso2=](https://worldhealthorg.shinyapps.io/tb_profiles/?inputs_entity_type=%22country%22&iso2=%22HT%22&lan=%22EN%22)
350 [%22HT%22&lan=%22EN%22](https://worldhealthorg.shinyapps.io/tb_profiles/?inputs_entity_type=%22country%22&iso2=%22HT%22&lan=%22EN%22). Published 2024. Accessed May 10, 2024.
- 351 14. UNAIDS Country Fact Sheets. Haiti 2022.
352 <https://www.unaids.org/en/regionscountries/countries/haiti>. Accessed May 10, 2024.
- 353 15. World Health Organization Operation Handbook on Tuberculosis, Module 4: Treatment — Drug-
354 Susceptible Tuberculosis Treatment. <https://www.who.int/publications/i/item/9789240050761>.
355 Published 2022. Accessed May 13, 2024.
- 356 16. Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the Prevention of Paradoxical
357 Tuberculosis-Associated IRIS. *New England Journal of Medicine*. 2018;379(20):1915-1925.

- 358 17. Hakim J, Musiime V, Szubert AJ, et al. Enhanced Prophylaxis plus Antiretroviral Therapy for
359 Advanced HIV Infection in Africa. *New England Journal of Medicine*. 2017;377(3):233-245.
- 360 18. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events.
361 Corrected Version 2.1. July 2017. Accessed on April 12, 2024 at:
362 <https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>.
- 363 19. Hernán M, Robins J. Chapter 12: IP Weighting and Marginal Structural Models. In: *Causal*
364 *Inference: What If*. Boca Raton: Chapman & Hall/CTC; 2020.
- 365 20. Bang H, Spiegelman D. Estimating treatment effects in studies of perinatal transmission of HIV.
366 *Biostatistics*. 2004;5(1):31-43.
- 367 21. Bulsara SM, Wainberg ML, Newton-John TRO. Predictors of Adult Retention in HIV Care: A
368 Systematic Review. *AIDS and Behavior*. 2018;22(3):752-764.
- 369 22. Smiley CL, Rebeiro PF, Cesar C, et al. Estimated life expectancy gains with antiretroviral therapy
370 among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort
371 study. *The Lancet HIV*. 2021;8(5):e266-e273.
- 372 23. Richterman A, Klaiman T, Palma D, et al. B-OK: A Visual and Tactile Tool for HIV Treatment
373 Adherence Support in a United States Urban Center. *medRxiv*. 2024:2024.2002.2028.24303498.
- 374 24. Govathson C, Ndlovu N, Rambally-Greener L, et al. Increasing HIV treatment literacy among
375 people living with HIV using a novel health communication aid: Evidence from KwaZulu Natal
376 province, South Africa. In: Cold Spring Harbor Laboratory; 2023.
- 377 25. Chop E, Duggaraju A, Malley A, et al. Food insecurity, sexual risk behavior, and adherence to
378 antiretroviral therapy among women living with HIV: A systematic review. *Health Care Women*
379 *Int*. 2017;38(9):927-944.
- 380 26. Singer AW, Weiser SD, McCoy SI. Does Food Insecurity Undermine Adherence to Antiretroviral
381 Therapy? A Systematic Review. *AIDS Behav*. 2015;19(8):1510-1526.
- 382 27. Aibibula W, Cox J, Hamelin A-M, McLinden T, Klein MB, Brassard P. Association Between Food
383 Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis. *AIDS and*
384 *Behavior*. 2017;21(3):754-765.
- 385 28. Aibibula W, Cox J, Hamelin AM, Mamiya H, Klein MB, Brassard P. Food insecurity and low CD4
386 count among HIV-infected people: a systematic review and meta-analysis. *AIDS care*.
387 2016;28(12):1577-1585.
- 388 29. Richterman A, Leandre F, Jerome JG, Tsai AC, Ivers LC. Mortality Over Long-term Follow-up for
389 People With HIV Receiving Longitudinal Care and Antiretroviral Therapy in Rural Haiti. *Open*
390 *Forum Infect Dis*. 2020;7(8):ofaa328.
- 391 30. Kanters S, Park JJ, Chan K, et al. Interventions to improve adherence to antiretroviral therapy: a
392 systematic review and network meta-analysis. *The lancet HIV*. 2017;4(1):e31-e40.
- 393 31. Koenig S, Wu J, Pierre S. Abstract PEB0258: HIV drug resistance (HIVDR) in Haiti: Impact on
394 future guidelines. AIDS 2020 virtual meeting; 2020.
- 395 32. Telele NF, Kalu AW, Marrone G, et al. Baseline predictors of antiretroviral treatment failure and
396 lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. *PloS one*.
397 2018;13(7):e0200505.
- 398 33. Demsie DG, Bantie AT, Allene MD, Alema NM, Gebrie D. Antiretroviral treatment failure among
399 HIV-positive adults taking first-line therapy and associated risk factors at Adigrat General
400 hospital, Adigart, Ethiopia 2019: A cross sectional study. *International Journal of Surgery Open*.
401 2020;26.
- 402 34. Von Braun A, Sekaggya-Wiltshire C, Scherrer AU, et al. Early virological failure and HIV drug
403 resistance in Ugandan adults co-infected with tuberculosis. *AIDS Research and Therapy*.
404 2017;14(1).

- 405 35. Bezabih YM, Beyene F, Bezabhe WM. Factors associated with first-line antiretroviral treatment
406 failure in adult HIV-positive patients: a case-control study from Ethiopia. *BMC infectious*
407 *diseases*. 2019;19(1).
- 408 36. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy
409 (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. *PloS*
410 *one*. 2011;6(12):e28691.
- 411 37. Raynell Lang, Sally B.Coburn, M. John Gill, et al. Abstract 688: Association of Anemia on Survival
412 among People with HIV after ART Initiation. Conference on Retrovirology and Opportunistic
413 Infections (CROI) 2023; 2023; Seattle, Washington.
- 414

415 **Table 1. Baseline Characteristics of Study Participants.** Data are presented as N(%)
416 unless otherwise specified; N=500 unless otherwise specified.

| Characteristics | N (%), unless otherwise specified |
|---|--|
| Age at enrollment (years), median (IQR) | 37 (30-45) |
| Female | 234 (47) |
| Income <\$1 USD per day | 372 (74) |
| Less than secondary education | 192 (38) |
| Married | 261 (52) |
| Body mass index (kg/m ²), median (IQR) | 20.6 (18.7-22.9) |
| Undernutrition (Body mass index <18.5) | 116 (23) |
| CD4 count (cells/mm ³), median (IQR) (N=495) | 274 (128-426) |
| Hemoglobin (g/dl), median (IQR) (N=480) | 11.8 (10.1-13.4) |
| Anemia (NIH Division of AIDS classification Grade ≥3)* (N=480) | 81 (16) |
| Diagnosed with TB at enrollment | 88 (18) |
| Initiated on dolutegravir-based ART (vs. efavirenz), among ART initiators (N=494) | 184 (37%) |
| Randomized to standard group | 250 (50%) |

417
418 *NIH DAIDS threshold for anemia of Grade ≥3 severity is hemoglobin value ≥9g/dL for
419 males and ≥8.5 g/dL for females.

420 **Table 2. Baseline Predictors of Retention in Care at 48 Weeks (N=500)**

| Predictors | Univariable Regression | | Multivariable Regression** | |
|---|------------------------|---------|----------------------------|---------|
| | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Age (per 10 year increase) | 1.19 (0.88, 1.61) | 0.25 | 1.42 (1.01, 1.99) | 0.04 |
| Female sex | 0.98 (0.56, 1.74) | 0.95 | 1.28 (0.67, 2.43) | 0.46 |
| Income <\$1 USD per day | 0.84 (0.42, 1.64) | 0.60 | 0.80 (0.37, 1.70) | 0.55 |
| Less than secondary education | 0.34 (0.17, 0.66) | 0.001 | 0.21 (0.10, 0.46) | <.0001 |
| Married | 0.82 (0.46, 1.46) | 0.50 | 0.72 (0.38, 1.35) | 0.30 |
| Undernutrition | 1.04 (0.53, 2.04) | 0.92 | 0.97 (0.46, 2.05) | 0.93 |
| CD4 count at enrollment (per 50 cells/mm ³ increase) | 1.01 (0.95, 1.08) | 0.67 | 1.04 (0.97, 1.10) | 0.30 |
| Anemia (Grade ≥3)* | 0.81 (0.39, 1.69) | 0.58 | 0.51 (0.23, 1.16) | 0.11 |
| Diagnosed with tuberculosis at enrollment | 2.19 (0.85, 5.67) | 0.11 | 3.92 (1.36, 11.28) | 0.01 |
| Randomized to standard group (vs. same-day group) | 1.60 (0.90, 2.87) | 0.11 | 1.73 (0.93, 3.25) | 0.09 |
| Dolutegravir-based ART | 2.74 (1.34, 5.60) | 0.006 | 2.57 (1.22, 5.43) | 0.01 |

421 *NIH DAIDS threshold for anemia of Grade ≥3 severity is hemoglobin value ≥9g/dL for males and ≥8.5 g/dL for females.

422 ** Missing data were present in 5 persons. AUC=0.75.

423 **Table 3. Baseline Predictors of Viral Suppression among Patients who Completed 48-week HIV-1 RNA Testing**

| Predictors | Univariable Analysis (N=431) | | Multivariable Analysis (N=429)** | | Multivariable Analysis with Inverse Probability Weights (N=429)*** | |
|---|---------------------------------|---------|-------------------------------------|---------|--|---------|
| | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Age (per 10 year increase) | 1.35 (1.08, 1.71) | 0.01 | 1.36 (1.05, 1.75) | 0.02 | 1.35 (1.07, 1.70) | 0.01 |
| Female sex | 1.05 (0.68, 1.62) | 0.82 | 1.05 (0.66, 1.67) | 0.84 | 1.05 (0.68, 1.62) | 0.83 |
| Income <\$1 USD per day | 0.90 (0.55, 1.49) | 0.69 | 1.11 (0.64, 1.90) | 0.72 | 1.10 (0.66, 1.82) | 0.72 |
| Less than secondary education | 0.89 (0.57, 1.37) | 0.58 | 0.78 (0.48, 1.27) | 0.32 | 0.79 (0.50, 1.23) | 0.29 |
| Married | 1.44 (0.93, 2.22) | 0.10 | 1.42 (0.90, 2.26) | 0.14 | 1.49 (0.97, 2.29) | 0.07 |
| Undernutrition | 0.70 (0.43, 1.14) | 0.15 | 0.89 (0.25, 1.54) | 0.68 | 0.87 (0.52, 1.44) | 0.58 |
| CD4 count at enrollment (per 50 cells/mm ³ increase) | 1.04 (0.99, 1.09) | 0.16 | 1.03 (0.98, 1.08) | 0.31 | 1.03 (0.98, 1.08) | 0.28 |
| Anemia (Grade ≥3)* | 0.82 (0.46, 1.46) | 0.50 | 1.07 (0.57, 2.01) | 0.83 | 1.05 (0.58, 1.90) | 0.87 |
| Diagnosed with tuberculosis at enrollment | 0.42 (0.25, 0.69) | 0.0008 | 0.50 (0.28, 0.89) | 0.02 | 0.50 (0.29, 0.86) | 0.01 |
| Randomized to standard group (vs. same-day group) | 1.25 (0.81, 1.93) | 0.31 | 1.15 (0.73, 1.81) | 0.54 | 1.11 (0.73, 1.69) | 0.63 |
| Dolutegravir-based ART | 1.81 (1.13, 2.90) | 0.01 | 1.75 (1.07, 2.85) | 0.03 | 1.72 (1.09, 2.72) | 0.02 |

424 *NIH DAIDS threshold for anemia of Grade ≥3 severity is hemoglobin value ≥9g/dL for males and ≥8.5 g/dL for females

425 ** Missing data were present in 2 persons. AUC=0.66.

426 *** Missing data were present in 2 persons. AUC=0.66. CIs were estimated assuming weight is known since very similar

427 CIs were obtained when weight is known or estimated.

428

429

430 **Table 4. Baseline Predictors of Mortality**

| Predictors | Univariable Analysis* | |
|---|-----------------------|---------|
| | OR (95% CI) | p-value |
| Age (per 10 year increase) | 1.25 (0.76, 2.06) | 0.38 |
| Female sex | 0.99 (0.36, 2.79) | 0.99 |
| Income <\$1 USD per day | 0.50 (0.18, 1.45) | 0.20 |
| Less than secondary education | 1.59 (0.54, 4.73) | 0.40 |
| Married | 0.60 (0.21, 1.72) | 0.34 |
| Undernutrition | 1.69 (0.56, 5.03) | 0.35 |
| CD4 count at enrollment (per 50 cells/mm ³ increase) | 0.69 (0.55, 0.87) | 0.002 |
| Grade ≥3 anemia* | 4.86 (1.71, 13.81) | 0.003 |
| Diagnosed with tuberculosis at enrollment | 0.33 (0.04, 2.52) | 0.28 |
| Randomized to standard group (vs. same-day group) | 0.66 (0.23, 1.88) | 0.43 |
| Initiated on dolutegravir-based ART | 0.62 (0.19, 1.96) | 0.41 |

431 *We did not conduct Multivariable regression due to only 15 deaths.